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A BNP variant increases GFR  
but does not lower blood pressure
Pan et al., Proc Natl Acad Sci USA 2009; 106: 11282–11287; doi:10.1073/pnas.0811851106
It is now clear that much of the complexity of the human pro-
teome is accounted for by alternative splicing of mRNA, since 
most, if not all, multiexonic genes generate alternatively spliced 
RNAs. Identification of splice variants of important ligands such 
as B-type natriuretic peptide (BNP) may provide clues about 
function and/or useful therapeutic tools. With this is mind, Pan 
et al. identified two expressed sequence tags consistent with 
intron 2 retention of the BNP transcript. Using primers specific 
for this transcript, they identified, in myocardium from fail-
ing human hearts, mRNA of BNP containing the first and sec-
ond exons plus the second intron. Using left ventricular tissue 
obtained before and after left ventricular assist device (LVAD) 
placement, they found that the level of expression of the alter-
natively spliced transcript was markedly decreased with the 
mechanical unloading associated with LVAD placement. They 
demonstrated that the alternatively spliced transcript resulted in 
expression of a peptide (present in failing myocardium) referred 
to as ASBNP. In vitro experiments revealed that, unlike BNP, both 
ASBNP and a shorter (carboxyl-truncated) variant of it, referred 
to as ASBNP.1, failed to stimulate cyclic guanosine monophos-
phate (cGMP) in human endothelial or vascular smooth mus-
cle cells or relax constricted human arterial rings. However, in 
freshly isolated glomeruli, ASBNP.1 and BNP had similar ability 
to stimulate cGMP. Further, in mesangial cells, ASBNP.1 and BNP 
stimulated cGMP to a similar degree, and the cGMP response 
was inhibited by an atrial natriuretic peptide (ANP) receptor 
antagonist, suggesting that the effect of ASBNP.1 was mediated 
through a particulate guanylyl cyclase-linked receptor. Binding 
studies showed that, when compared with BNP, ASBNP.1 is a 
very poor activator of natriuretic peptide receptor (NPR)-A and 
NPR-B, and has reduced binding to NPR-C, suggesting the pres-
ence of a receptor or receptor subtype in the kidney, to which 
ASBNP.1 is a ligand. Intravenous infusion of ASBNP.1 in dogs 
with heart failure increased glomerular filtration rate (GFR), diu-
resis, and natriuresis but did not change renal blood flow or arte-
rial pressure (Figure). These data suggest that ASBNP.1 retained 
the effects of BNP on renal cells but lacked the effects on vascular 
cells, and it appears that ASBNP.1 has renal-specific actions but 
lacks blood pressure−lowering effects. Although many questions 
remain, ASBNP.1 has significant potential as a probe of the ANP 
system and as a GFR-enhancing therapeutic agent.
Juan Oliver
Carbon monoxide restores function 
in chronic allograft nephropathy
Nakao et al., Am J Physiol Renal Physiol 2009; 297: F19–F26; doi:10.1152/
ajprenal.90728.2008
Carbon monoxide (CO) in cells can regulate multiple functions, and 
it appears to be important as a defense mechanism against cell stress 
such as heat shock, heavy metals, reactive oxygen species, lipopoly-
saccharide, and, of particular interest, inflammatory processes.
Despite much work, the half-life of renal allografts has remained 
unchanged for more than a decade. The most common clinical 
presentation of late allograft loss is referred to as chronic allograft 
nephropathy (CAN), defined as a progressive decrease in renal 
function plus a histopathological picture of interstitial fibrosis, 
tubular atrophy, vascular occlusions, and glomerulosclerosis. 
Thus, CAN is a poorly characterized clinicopathological entity 
probably caused by multiple factors. The cytoprotective action of 
CO led Neto et al. to treat kidney allograft recipients with inhaled 
CO, and they found that it effectively prevented CAN.1 In a recent 
communication, the same group of researchers examined whether 
CO could reverse established CAN and restore allograft function. 
They transplanted Lewis rat kidney grafts into binephrectomized 
allogenic Brown Norway rats under a brief period of tacrolimus 
administration. At day 60 after transplantation, development of 
CAN was apparent as shown by decreased creatinine clearance, 
significant proteinuria, and consistent histopathological findings. 
At this time, a group of recipient animals received a low dose of CO 
(20 ppm) by inhalation, which was continued until day 150 or ani-
mal death. Air-treated control recipients continued to worsen. In 
marked contrast, progression of CAN decreased or even reversed 
in the animals receiving CO during days 60–150. In these animals, 
there was a remarkable improvement in creatinine clearance and 
a decrease in proteinuria, and their median survival exceeded 150 
days (Figure). This provocative study demonstrates that CO is able 
to inhibit progression of the fibroinflammatory process of CAN 
and, at least in part, restore renal allograft function.
Juan Oliver
1Am J Physiol Renal Physiol 2006; 290: F324–F334.
Infusion of ASBNP.1 in a canine model of congestive heart failure increased 
GFR (a) without affecting mean arterial blood pressure (b).
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Long-term kidney graft functions with and without CO treatment on days 60–150. 
Sequential analysis of creatinine clearance, urinary protein, and recipient survival.
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Intravenous MSCs  
improve myocardial infarction  
repair by secreting TSG-6
Lee et al., Cell Stem Cell 2009; 5: 54–63; doi:10.1016/j.stem.2009.05.003
Administration of mesenchymal stem cells (MSCs, also known 
as mesenchymal stromal cells) accelerates repair in some forms 
of injury to adult organs, including the kidney. While some stud-
ies suggest that MSCs home to sites of injury, in many studies the 
cells were administered intravenously. Under these conditions, the 
functional improvements caused by the cells are somewhat sur-
prising, since they are trapped in the pulmonary circulation. For 
example, it has been postulated that MSCs accelerate kidney repair 
after acute kidney injury by secreting growth factors. To examine 
how MSCs trapped in the lung can enhance repair of the heart, 
brain, and other organs, Lee et al. intravenously infused human 
MSCs (hMSCs; 2 × 106) into mice and first examined the fate of the 
cells. They found that most of the cells were trapped as emboli in 
lung, and these cells disappeared, with a half-life of about 24 hours. 
Interestingly, the cells that disappeared from lung did not appear in 
any significant numbers in the six other organs examined (includ-
ing the kidneys): a total of approximately 4000 were recovered 
after 48 hours and 1000 after 96 hours. To examine their potential 
mechanism of action, the authors examined the changes in the 
mouse and human transcriptomes produced by the hMSCs in the 
lungs. Embolization with the cells upregulated and downregulated 
a variety of mouse and human transcripts. Focusing on genes of 
interest, after appropriate validation of the data, the authors found 
greater increases in the transcripts for SMAD6, colony-stimulating 
factor 1, vascular cell adhesion molecule-1, and tumor necrosis 
factor-α-stimulated gene-6 (TSG-6). The increase in TSG-6 was of 
particular interest because this protein was previously shown to be 
a powerful anti-inflammatory factor. To determine whether larger 
numbers of intravenously infused hMSCs appeared in the heart 
after myocardial infarction, hMSCs were infused into the tail veins 
of mice 1 day after infarct. The authors found that only 0.04% and 
0.148% of the infused cells were recovered in the infarcted hearts 
15 minutes and 24 hours after the infusion, respectively. Real-
time PCR demonstrated that human TSG-6 mRNA in lung was 
increased after infusions of hMSCs, and appropriate assays dem-
onstrated that both MSCs and TSG-6 decreased proinflammatory 
proteases in mice with infarction. Further, infusion of hMSCs of 
recombinant human TSG-6 (rhTSG-6) decreased infarct size (Fig-
ure), whereas hMSCs with a small interfering RNA knockdown of 
the TSG-6 gene had no effect. These exciting results indicate that 
the hMSCs trapped in the lung secreted TSG-6, and that TSG-6 
suppressed the excessive inflammatory response to myocardial inf-
arction so that it decreased proteolytic damage, subsequent fibrotic 
scarring, and the fall in cardiac function.
Juan Oliver
Safety and efficacy of drug-eluting 
and bare metal stents
Kirtane et al., Circulation 2009; 119: 3198–3206; doi:10.1161/
CIRCULATIONAHA.108.826479
Cardiovascular disease plays a large role in the morbidity and mor-
tality of patients with kidney disease. Among patients receiving per-
cutaneous angioplasty and stenting of their coronary arteries, the 
amount of time they need to take antiplatelet agents is dictated by 
the type of stent that they receive—drug-eluting or bare metal—
and has a direct impact on the timing of transplantation. There-
fore, knowing the relative risk and benefit of drug-eluting versus 
bare metal stents is essential. Now, a meta-analysis by Kirtane et al. 
combines 22 randomized controlled trials (RCTs) involving 9470 
patients and 34 observational studies reporting data on 182,901 
patients. Among the RCTs, drug-eluting stents did not improve 
mortality or recurrent myocardial infarction. However, target vessel 
revascularization was reduced by 55%. In the observational stud-
ies, drug-eluting stents were associated with better outcomes for all 
three events as compared with bare metal stents.
One methodological difference between data from RCTs and 
observational data discussed in the cardiology literature is that 
observational data include patients who receive the bare metal stents 
for ‘off-label’ indications, whereas trial data include only on-label 
indications. As approved by the US Food and Drug Administration, 
the current indications for drug-eluting stents are limited to short 
de novo (not recurrent or previously stented) lesions in coronary 
arteries measuring 2.5 mm or greater and 3.5 mm or less (sirolimus-
eluting stents) or 3.75 mm or less (paclitaxel-eluting stents) in diam-
eter. Use of drug-eluting stents for off-label indications has been 
estimated at nearly 50% of their total use and would include use in 
restenotic lesions, lesions in a bypass graft, a lesion longer than 28–30 
mm, or a smaller- or larger-diameter vessel or totally occluded ves-
sel. This meta-analysis may suggest that the success of drug-eluting 
stents in observational studies is likely related to selection bias for 
drug-eluting stents used both on and off label, that trial data cannot 
be applied to populations with more complicated coronary artery 
lesions, and that drug-eluting stents should be used more often 
among patients with more complicated coronary disease. However, 
the limitations of observational data and the fact that patients with 
kidney disease have more severe and complicated coronary lesions 
should be considered as well. The length of antiplatelet therapy is 
another critical factor in deciding whether or not to use drug-eluting 
stents. Longer antiplatelet therapy following implantation of drug-
eluting stents due to decreased endothelialization and subsequent 
stent thrombosis delays the timing of living related transplantation 
and activation on the deceased-donor list.
Lynda Szczech
Infarct size in a control mouse and in a mouse that received intravenous 
infusion of hMSCs. 
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